AcquisitionOther
SECOND SIGHT MEDICAL PRODUCTS INC acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
SECOND SIGHT MEDICAL PRODUCTS INC -> target · $8 million
• Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 • Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clini
Open source record (SEC) ↗